<DOC>
	<DOCNO>NCT01127295</DOCNO>
	<brief_summary>This biomedical study interventional type , multicenter , inter-regional . Patients hormono-depending breast cancer , indication adjuvant hormonotherapy treatment ( accord current treatment ) retain , enrol study . The main objective estimate correlation pharmacokinetic pharmacogenetic parameter adjuvant hormonal breast cancer treatment , first 3 year .</brief_summary>
	<brief_title>Pharmacology Adjuvant Hormonotherapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Patient 18 year old ( menopaused ) 2 . Invasive breast cancer nonmetastatic locally control surgery without radiotherapy . Previous treatment chemotherapy allow include trastuzumab 3 . Cancer hormoneexpressing ER / PR ( &gt; 10 % tumor cell Technical HIC ) 4 . Having stag explore bone , liver , lung show abnormality secondary ( subcentimeter tumor , stag necessary ) 5. WHO &lt; 2 6 . Before initiation adjuvant hormonal therapy ( tamoxifen , anastrozole , letrozole exemestane ) whatever approach choose investigator ( 5 year tamoxifen , 5 year antiaromatase sequential pattern ) 7. sign Consent collect specific procedure study 8 . Patient member national insurance scheme . 1 . Patient previously treat breast cancer receive hormonal therapy tamoxifen , anastrozole , letrozole exemestane regardless scheme 2 . Metastatic Breast cancer 3 . History another cancer diagnose within 5 year uncontrolled except carcinoma situ cervix carcinoma , nonmelanoma skin , breast cancer ( case , treatment hormone therapy stop least 6 month ) 4 . Any medical psychiatric condition laboratory abnormality severe acute chronic make inclusion patient study inappropriate opinion investigator 5 . Patient unable follow procedure , visit , examination describe study 6 . Pregnant woman nurse mother participate study 7 . Women childbearing age must use effective contraception study entry least three month end treatment 8 . Patient legal guardianship</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacogenetic</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>anti-aromatases</keyword>
	<keyword>breast cancer</keyword>
	<keyword>pharmacodynamy</keyword>
	<keyword>Observance</keyword>
</DOC>